{"issuance_frequency":"","notes_translated":{"fr":"L'AU nº 2 soutient la volonté du Canada de continuer à s'attaquer au risque important que la COVID-19 continue de représenter pour la santé et la sécurité des Canadiens.","en":"IO No. 2 supports Canada’s continued focus on dealing with the significant risk that COVID-19 continues to pose to the health and safety of Canadians."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"361e9ad4-c416-460a-ad7c-d402c5fe1302","metadata_created":"2021-05-28T19:01:07.055317","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-05-28T19:01:07.055323","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-05-28","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["COVID-19","ordonnance provisoire n ° 2","avis","essais cliniques","dispositifs médicaux","médicaments","risques","santé et sécurité"],"en":["COVID-19","Interim Order No. 2","notice","clinical trials","medical devices","drugs","risks","health and safety"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Note explicative sur le nouvel arrêté d’urgence pour faire avancer les essais cliniques en lien avec la COVID-19","en":"Explanatory note on new interim order to advance COVID-19 clinical trials"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"361e9ad4-c416-460a-ad7c-d402c5fe1302","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9b0d97f5-6a49-4fff-8c53-cd18edbad22d","related_relationship":"","name_translated":{"fr":"Note explicative sur le nouvel arrêté d’urgence pour faire avancer les essais cliniques en lien avec la COVID-19","en":"Explanatory note on new interim order to advance COVID-19 clinical trials"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Explanatory note on new interim order to advance COVID-19 clinical trials","language":["en"],"created":"2021-05-28T19:01:07.145364","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/interim-order-2-clinical-trials-medical-devices-drugs/explanatory-note.html","last_modified":null,"position":0,"revision_id":"bc018115-1bc7-4f81-9ad3-9c42ecff56a9","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"361e9ad4-c416-460a-ad7c-d402c5fe1302","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"8d6c0376-7b45-4071-932e-87c5f33080e7","related_relationship":"","name_translated":{"fr":"Note explicative sur le nouvel arrêté d’urgence pour faire avancer les essais cliniques en lien avec la COVID-19","en":"Explanatory note on new interim order to advance COVID-19 clinical trials"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Explanatory note on new interim order to advance COVID-19 clinical trials","language":["fr"],"created":"2021-05-28T19:01:07.145370","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/arrete-urgence-no-2-cliniques-instruments-medicaux-drogues/note-explanative.html","last_modified":null,"position":1,"revision_id":"bc018115-1bc7-4f81-9ad3-9c42ecff56a9","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2021-04-28 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"361e9ad4-c416-460a-ad7c-d402c5fe1302","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"IO No. 2 supports Canada’s continued focus on dealing with the significant risk that COVID-19 continues to pose to the health and safety of Canadians.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Explanatory note on new interim order to advance COVID-19 clinical trials","revision_id":"bc018115-1bc7-4f81-9ad3-9c42ecff56a9"}